Fulgent Genetics (NASDAQ:FLGT - Free Report) had its target price decreased by Piper Sandler from $26.00 to $22.00 in a research report report published on Monday morning,Benzinga reports. Piper Sandler currently has a neutral rating on the stock.
Fulgent Genetics Trading Up 3.4 %
FLGT traded up $0.67 during midday trading on Monday, hitting $20.10. 192,051 shares of the company traded hands, compared to its average volume of 179,620. The company has a market capitalization of $609.03 million, a price-to-earnings ratio of -3.52 and a beta of 1.51. Fulgent Genetics has a 52-week low of $18.76 and a 52-week high of $30.68. The business has a 50 day simple moving average of $21.01 and a two-hundred day simple moving average of $21.44.
Insider Transactions at Fulgent Genetics
In related news, CEO Ming Hsieh sold 2,313 shares of the business's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total transaction of $52,805.79. Following the transaction, the chief executive officer now directly owns 707,275 shares in the company, valued at approximately $16,147,088.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have sold 4,324 shares of company stock valued at $98,717 over the last ninety days. Insiders own 31.76% of the company's stock.
Institutional Trading of Fulgent Genetics
Several institutional investors have recently made changes to their positions in the company. Asset Dedication LLC acquired a new stake in shares of Fulgent Genetics during the second quarter worth about $33,000. nVerses Capital LLC acquired a new position in shares of Fulgent Genetics in the 2nd quarter valued at $43,000. Signaturefd LLC grew its holdings in shares of Fulgent Genetics by 103.6% during the second quarter. Signaturefd LLC now owns 2,225 shares of the company's stock worth $44,000 after purchasing an additional 1,132 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in Fulgent Genetics during the second quarter worth approximately $63,000. Finally, Gladius Capital Management LP acquired a new position in shares of Fulgent Genetics in the 3rd quarter valued at $81,000. Hedge funds and other institutional investors own 48.06% of the company's stock.
About Fulgent Genetics
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Featured Articles
Before you consider Fulgent Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulgent Genetics wasn't on the list.
While Fulgent Genetics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
